was 1022034, including 2033 active cases, 1009369 recoveries and 10632 deaths. as of 30 august, the total number of covid cases was 1051297, including 2300 active cases, 1038318 recoveries and 10679 deaths. as of 10 september, the total number of covid cases was 1053666, including 666 active cases, 1042307 cures and 10693 deaths. as of 18 september, the total number of covid cases was 1054254, including 439 active cases, 1043118 cures and 10697 fatal cases. as of 24 september, the total number of covid cases was 1054683, including 337 active cases, 1043643 cures and 10703 deaths. covid-19 vaccines with approval for emergency or conditional usage union minister for health & family welfare, dr. harsh vardhan visiting the gtb hospital, shahdara to review the preparedness of dry run of covid-19 vaccine, in delhi on january 2, 2021. main article: covid-19 vaccine covishield on january 1, 2021, the drug controller general of india, approved the emergency or conditional use of astrazeneca's covid-19 vaccine azd1222 (marketed as covishield). covishield is developed by the university of oxford and its spin-out company, vaccitech. it is a viral vector vaccine based on replication-deficient adenovirus that causes cold in chimpanzees. it can be stored, transported and handled at normal refrigerated conditions (28 degrees celsius/ 36-46 degrees fahrenheit). it has a shelf-life of at least six months. on 12 january 2021 first batches of covishield vaccine was despatched from the serum institute of india. covaxin on january 2, 2021, bbv152 (marketed as covaxin), first indigenous vaccine, developed by bharat biotech in association with the indian council of medical research and national institute of virology received approval from the drug controller general of india for its emergency or conditional usage. on 14 january 2021 first batches of covaxin vaccine was despatched from the bharat biotech, albeit it was still in the third phase of testing. others on 19 may 2021, dr reddy's labs received emergency use authorisation for anti-covid drug 2-dg. on 21 february, 2022, drugs controller general of india granted approval to biological e's covid-19 vaccine corbevax, that can be used for children between 12 and 18 years of age. on 21 october 2021, india completed administering of one billion covid vaccines in the country. on 8 january 2022, india crossed 1.5 billion covid vaccines milestone in the country. on 19 february 2022, india crossed 1.75 billion covid vaccines milestone in the country.